Showing results (71-80 of 117) with videos related to

Sort By:
Pageof 12
Cancer Chemotherapy and Pharmacology|November 14, 2013
Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinomaCharles S Harmon, Samuel E DePrimo, Robert A Figlin, et al.
European Journal of Cancer (Oxford, England : 1990)|November 26, 2023
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohortEric Jonasch, Todd M Bauer, Kyriakos P Papadopoulos, et al.
The Lancet. Oncology|October 26, 2007
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II studyOlivier Rixe, Ronald M Bukowski, M Dror Michaelson, et al.
Cancer|November 25, 2010
Sunitinib rechallenge in metastatic renal cell carcinoma patientsIvan N Zama, Thomas E Hutson, Paul Elson, et al.
The Lancet. Oncology|April 3, 2023
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 studyToni K Choueiri, David F McDermott, Jaime Merchan, et al.
The Oncologist|August 11, 2019
Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trialDaniel J George, Colin Hessel, Susan Halabi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2013
A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastasesRichard J Lee, Philip J Saylor, M Dror Michaelson, et al.
Nature Medicine|April 23, 2021
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysisToni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2017
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN TrialToni K Choueiri, Susan Halabi, Ben L Sanford, et al.
Clinical Genitourinary Cancer|May 9, 2014
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancerGuru Sonpavde, Gregory R Pond, Andrew J Armstrong, et al.
Pageof 12